BioSpace News Archive

RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 332 owned and/or operated outpatient imaging centers, announced the amendment of its senior secured first lien credit agreement to increase the amount of the revolving commitments thereunder by $57.5 million.

A HALAL Certified Product Means that the Product is Permissible or Acceptable in Accordance with Islamic Law

Axogen, Inc., a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, announced that Karen Zaderej, chairman, CEO, and president will present at the Cantor Virtual Global Healthcare Conference.

XORTX Therapeutics Inc. a late clinical stage pharmaceutical development company focused on kidney disease, is pleased to announce that the Company has filed its pre-IND meeting request with the U.S. FDA.

Clinical studies both underway and planned for patients with COVID-19 pneumonia in the U.S., U.K., and Brazil Proposed multi-center U.S. randomized clinical program in regulatory submission following the treatment of patients via expanded access programs In Brazil, patient recruitment completed for proof of principle (POP) clinical study; potential progression into follow-on randomized study expected early Q4 2020 Nomacopan selected by AGILE COVID-19 clinical trial initiative in t

Mindset Pharma (“Mindset”), a leading drug discovery and development business focused on next-generation psychedelic medicines to treat neuropsychiatric indications with unmet needs, announces today the preliminary screening results of certain patent-pending compounds.

- Study met primary and secondary endpoints of significantly lowering the risk of developing a second primary generalized tonic-clonic seizure (PGTCS) during a 24-week treatment and a significantly higher rate of freedom from PGTCS during the treatment period compared with placebo - Lacosamide was generally tolerated by patients enrolled in the study - Regulatory reviews, based, in part, on these data, are currently underway in the U.S., EU, Japan, and Australia

Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated drug profile in safety and pharmacokinetics in cancer patients Joined the global effort against COVID-19 with plonmarlimab (TJM2) study which represents the first double-blind, placebo-controlled study evaluating anti-GM-CSF antibody in severe COVID-19 patients

− Former Senior Vice President of the Oncology Business Unit at Genentech; Brings Over 25 Years of Extensive Leadership and Commercial Experience in the Pharmaceutical Industry −

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the U.S. Food and Drug Administration (FDA) has issued a “safe to proceed” notice for Can-Fite’s Investigational N